Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment. Front Immunol. 2023;14:1208567. https://pubmed.ncbi.nlm.nih.gov/37600808/ https://doi.org/10.3389/fimmu.2023.1208567

Maccari ME, Wolkewitz M, Schwab C, et al; European Society for Immunodeficiencies Registry Working Party. Activated phosphoinositide 3-kinase δ syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023;152(4):984-996.e10. http://www.jacionline.org/article/S0091674923008126/fulltext https://doi.org/10.1016/j.jaci.2023.06.015 PMID:37390899

Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210-218.e9. https://pubmed.ncbi.nlm.nih.gov/27221134/ https://doi.org/10.1016/j.jaci.2016.03.022 PMID:27221134

Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4. https://doi.org/10.1016/j.jaci.2016.06.021 PMID:27555459

Peshko D, Kulbachinskaya E, Korsunskiy I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(6):1929-1957.e5. http://www.jaci-inpractice.org/article/S2213219819301795/fulltext https://doi.org/10.1016/j.jaip.2019.02.013 PMID:30797077

Badia X, Gil A, Poveda-Andrés JL, Shepherd J, Tort M. Analysing criteria for price and reimbursement of orphan drugs in Spain. Farm Hosp. 2019;43(4):121-127. https://www.revistafarmaciahospitalaria.es//es-analysing-criteria-for-price-reimbursement-articulo-S1130634323002088 PMID:31276443

Gilabert-Perramon A, Torrent-Farnell J, Catalan A, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33(1):111-120. https://doi.org/10.1017/S0266462317000149 PMID:28434413

Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making – emerging good practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Heal [Internet]. 2016 Mar 1 [cited 2023 Dec 18];19(2):125-137. http://www.valueinhealthjournal.com/article/S1098301515300152/fulltext

Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making – an introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Heal [Internet]. 2016 Jan 1 [cited 2023 Dec 18];19(1):1-13. http://www.valueinhealthjournal.com/article/S1098301515051359/fulltext

Badia X, Chugani D, Abad MR, et al. Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain. Expert Opin Orphan Drugs. 2019;7(7-8):363-372. https://doi.org/10.1080/21678707.2019.1652163

Badia X, Calleja M, Mirco A, Poveda J, Gil A. HT6 – Do Spain and Portugal evaluators and decision makers give the same importance to evaluation criteria of innovative medicines? Value Heal [Internet]. 2018 Oct 1 [cited 2023 Dec 18];21:S9. http://www.valueinhealthjournal.com/article/S1098301518333527/fulltext

Maccari ME, Abolhassani H, Aghamohammadi A, et al. disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol. 2018;9:543. https://doi.org/10.3389/fimmu.2018.00543 PMID:29599784

Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410-421.e7. https://doi.org/10.1016/j.jaci.2021.04.036 PMID:34033842

Okano T, Imai K, Tsujita Y, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1. J Allergy Clin Immunol. 2019;143(1):266-275. http://www.jacionline.org/article/S0091674918307073/fulltext https://doi.org/10.1016/j.jaci.2018.04.032 PMID:29778502

Berglund LJ. Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective. J Clin Immunol. 2023;44(1):34. https://link.springer.com/article/10.1007/s10875-023-01626-0 https://doi.org/10.1007/s10875-023-01626-0 PMID:38148368

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making. 2012;32(2):376-388. https://doi.org/10.1177/0272989X11416870 PMID:21987539

Fahy WA, Homayoun-Valiani F, Cahn A, et al. Nemiralisib in patients with an acute exacerbation of COPD: placebo-controlled, dose-ranging study. Int J Chron Obstruct Pulmon Dis. 2021;16:1637-1646. https://www.dovepress.com/nemiralisib-in-patients-with-an-acute-exacerbation-of-copd-placebo-con-peer-reviewed-fulltext-article-COPD https://doi.org/10.2147/COPD.S309320 PMID:34113095

Begg M, Amour A, Jarvis E, et al. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome. Pulm Pharmacol Ther. 2023;79:102201. https://doi.org/10.1016/j.pupt.2023.102201 PMID:36841351

Diaz N, Juarez M, Cancrini C, et al. Seletalisib for activated PI3Kδ syndromes: open-label phase 1b and extension studies. J Immunol. 2020;205(11):2979-2987. https://doi.org/10.4049/jimmunol.2000326 PMID:33115853

Gasol M, Paco N, Guarga L, Bosch JÀ, Pontes C, Obach M. Early access to medicines: use of multicriteria decision analysis (MCDA) as a decision tool in Catalonia (Spain). J Clin Med. 2022;11(5):1353. https://pubmed.ncbi.nlm.nih.gov/35268443/ https://doi.org/10.3390/jcm11051353 PMID:35268443